Annals of Oncology 13:632-636, 2001
© 2001 European Society for Medical Oncology
Clinical Investigations |
The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of
-fetoprotein or ß-human chorionic gonadotrophin: report of two cases
1Service de Cancérologie and 2Laboratoire dAnatomopathologie, Hôpital Paul Brousse, Villejuif, France
Received 9 January 2001; revised and accepted 11 June 2001.
Abstract
The chemotherapy of advanced gastric adenocarcinomas (GAs) is based on agents such as cisplatin, 5-fluorouracil and anthracyclins. Reproducible objective response rates are reported as ~40%. However, the median survival remains short, not exceeding 10 months. Amongst GA, a subset of tumours with increased plasma
-fetoprotein (
FP) and/or ß human chorionic gonadotrophin (ßHCG) levels form a well-defined histopathological entity. This subgroup has been associated with poor prognosis, due to the presence of poorly differentiated and rapidly proliferating cells. No specific chemotherapy has been proposed for this particular form of GA. We report two cases of patients with GA and hypersecretion of
FP and/or ßHCG. Despite bulky liver metastases and resistance to two standard chemotherapy regimens, both patients exhibited sensitivity to chemotherapy combining bleomycin, oxaliplatin and etoposide. These results suggest that patients with this particular subset of GA may benefit from chemotherapy regimens similar to those given to germ-cell tumour patients.
Key words: adenocarcinoma,
-fetoprotein, ß human chorionic gonadotrophin, chemotherapy, gastric